The head of evidence-based medicine at Milan's health authority Alberto Donzelli has pulled down criticism of Merck's cholesterol drug ezetimibe from his website, after the drugmaker sent two cease-and-desist letters.
Editorial says risk is small, researchers say it could be clinically relevant.
Novartis no longer has a lock on the Diovan market: the FDA approved Ranbaxy's generic, which will be made in the US.
Gene mutations lead researchers to rethink ways to protect the heart.
Two studies found two different facets of statin therapy—one found patients moved less a year after starting their regimens, and another that the drugs upped the diabetes risk for some.
The company signed a deal with AstraZeneca in which high-risk heart disease patients can bypass step therapy and go straight to the branded cholesterol fighter.
The company is settling around 4,000 cases for around $162,500 apiece.
The drugmaker is set to start patient testing.
Novartis says the FDA wants more serelaxin efficacy data.
GlaxoSmithKline announced Tuesday its Phase-III drug from the Human Genome Sciences acquisition failed to hit its primary endpoint.
Zontivity (vorapaxar) was approved for patients who have already suffered a heart attack or have arterial blockages in the legs.
The company's 11-country poll found overall awareness about heart failure to be low. The geographic bloc is in the same bucket as the US in terms of mortality rates.
The drugmaker said successful results prompted an independent Data Monitoring Committee to recommend stopping the trial. The news follows an uneven week of pipeline drug news.
Analyses by Jefferies indicate that although doctors are interested in the experimental anti-cholesterol drugs, CV data will be a critical differentiator.
The state's attorney general says the drugmakers did not reveal that the drug could have a different impact—if any—on patients with East Asian or Pacific Islander heritage.
Researchers find that Canada has been a significant contributor to Zetia sales.
Researchers say saturated fat may not cause heart disease, but critics say the study is too narrow.
The FDA approved the blood drug to prevent deep vein thrombosis and pulmonary embolism among hip- and knee-replacement patients. The approval means BMS and Pfizer may encroach upon the territory of J&J's Xarelto.
The Thousand Oaks, Calif. company says its cholesterol-lowering antibody hit its clinical trial endpoint among rare disease patients.
The company said it used "inappropriate expressions" in promotions of a blood pressure medication.
Roche said an onartuzumab and Tarceva mix did not help advanced non-small cell lung cancer patients with MET-positive tumors.
The FDA rejected J&J's expanded indication request a third time.
The Cleveland Clinic finds that 75% of Americans don't worry about dying of heart disease, even though it's the country's leading killer.
A sealed complaint, reported on by the Wall Street Journal, builds on concerns that were already surrounding the now-controversial Plato study.
Positive results from a Phase-III trial edge Amgen's evolocumab closer to approval, though it's still behind rivals in the PCSK9 race.
The FDA panel voted 10-1 for the drug. The assessment included patient weight and health recommendations.
An FDA committee is poised to review a new Primatene Mist in February.
The warfarin replacement will be evaluated in a post-trial safety study, regulators said last Friday.
The American College of Cardiology is contributing its Pinnacle registry to identify clinical trial patients.
The fine is for Pradaxa documents that have gone missing. The company is accused of hiding risk information about its blood thinner.